Fine-tuning the normal tissue objective in eclipse for lung stereotactic body radiation therapy

被引:15
作者
Bell, James P. [1 ]
Patel, Pretesh [2 ]
Higgins, Kristin [2 ]
McDonald, Mark W. [3 ]
Roper, Justin [3 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
[2] Emory Univ, Winship Canc Inst, 1356 Clifton Rd NE,Bldg C, Atlanta, GA 30322 USA
[3] Hosp Corp Amer, Sarah Cannon Canc Ctr, Dept Radiat Oncol, 2410 Patterson St,Basement Level, Nashville, TN 37203 USA
关键词
NTO; Fall-off; SBRT; UNIFIED DOSIMETRY INDEX; MODULATED ARC THERAPY; QUALITY-ASSURANCE; RADIOTHERAPY; DELIVERY; CANCER; TUMORS;
D O I
10.1016/j.meddos.2017.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to characterize the effects of the normal tissue objective (NTO) on lung stereotactic body radiation therapy (SBRT) dose distributions. The NTO is a spatially varying constraint used in Eclipse to limit dose to normal tissues by steepening the dose gradient. However, the multitude of potential NTO setting combinations challenges optimal NTO tuning. In the present study, a broad range of NTO settings are investigated for lung SBRT treatment planning with volumetric modulated arc therapy(VMAT). Ten prior lung SBRT cases were replanned using NTO priorities of 1, 50, 100, 200, 500, and 999 in combination with fall-off values of 0.01, 0.05, 0.10, 0.15, 0.20, 0.30, 0.50, 1.00, and 5.00 mm(-1) and the automatic NTO. NTO distances to planning target volume (PTV), start dose, and end dose were 1 mm, 100%, and 10%, respectively, for all 600 plans. Prescription dose covered 95% of the PTV. The following metrics were recorded: conformity index (CI), ratio of the 50% prescription isodose volume to PTV (R-50%), maximum dose 2cm away from PTV (D-2cm), lung volume of >= 20 Gy (V-20Gy), maximum PTV dose (PTVmax), and monitor units (MUs). Differences between prior plans and NTO plans were evaluated using the Wilcoxon signed-rank test. Different combinations of NTO settings resulted in wide-ranging plan quality metrics: CI (1.00 to 1.54), R-50% (3.95 to 7.57), D-2cm (33.4% to 67.9%), V-20Gy (1.66% to 2.75%), MU (1.81 cGy(-1) to 4.69 cGy(-1)), and PTVmax (118% to 175%). Although no settings were optimal for all metrics, a fall-off of 0.15 mm(-1) and a priority of 500 best satisfied institutional criteria. Compared with prior plans, NTO plans resulted in significantly lower R555 (4.00 vs 4.35, p= 0.002), lower V-20Gy (1.22% vs 1.32%, p=0.006), and higher PTVmax (138% vs 122%, p=0.002).All of the prior and well-tuned NTO plans met Radiation Therapy Oncology Group (RTOG) 0813 guidelines. Lung SBRT dose distributions were characterized across a range of NTO settings. NTO plans with well-tuned settings compared favorably with prior plans. (C) 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:344 / 350
页数:7
相关论文
共 18 条
[1]   Unified dosimetry index (UDI): a figure of merit for ranking treatment plans [J].
Akpati, Hilary ;
Kim, ChangSeon ;
Kim, Bong ;
Park, Tae ;
Meek, Allen .
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2008, 9 (03) :99-108
[2]   Stereotactic body radiation therapy: The report of AAPM Task Group 101 [J].
Benedict, Stanley H. ;
Yenice, Kamil M. ;
Followill, David ;
Galvin, James M. ;
Hinson, William ;
Kavanagh, Brian ;
Keall, Paul ;
Lovelock, Michael ;
Meeks, Sanford ;
Papiez, Lech ;
Purdie, Thomas ;
Sadagopan, Ramaswamy ;
Schell, Michael C. ;
Salter, Bill ;
Schlesinger, David J. ;
Shiu, Almon S. ;
Solberg, Timothy ;
Song, Danny Y. ;
Stieber, Volker ;
Timmerman, Robert ;
Tome, Wolfgang A. ;
Verellen, Dirk ;
Wang, Lu ;
Yin, Fang-Fang .
MEDICAL PHYSICS, 2010, 37 (08) :4078-4101
[3]   Efficacy and Toxicity Analysis of NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC) [J].
Bezjak, A. ;
Paulus, R. ;
Gaspar, L. E. ;
Timmerman, R. D. ;
Straube, W. L. ;
Ryan, W. F. ;
Garces, Y. ;
Pu, A. T. ;
Singh, A. K. ;
Videtic, G. M. ;
McGarry, R. C. ;
Iyengar, P. ;
Pantarotto, J. R. ;
Urbanic, J. J. ;
Sun, A. ;
Daly, M. E. ;
Grills, I. S. ;
Normolle, D. P. ;
Bradley, J. D. ;
Choy, H. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02) :S8-S8
[4]   Size matters: A comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) [J].
Dunlap, Neal E. ;
Larner, James M. ;
Read, Paul W. ;
Kozower, Benjamin D. ;
Lau, Christine L. ;
Sheng, Ke ;
Jones, David R. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (03) :583-589
[5]   Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer [J].
Falkson, C. B. ;
Vella, E. T. ;
Yu, E. ;
El-Mallah, M. ;
Mackenzie, R. ;
Ellis, P. M. ;
Ung, Y. C. .
CURRENT ONCOLOGY, 2017, 24 (01) :E44-E49
[6]  
Khan F.M., 2014, KHANS PHYS RAD THERA
[7]  
Kim S, 2015, J RADIOSURGERY SBRT, V3, P215
[8]   Task Group 142 report: Quality assurance of medical accelerators [J].
Klein, Eric E. ;
Hanley, Joseph ;
Bayouth, John ;
Yin, Fang-Fang ;
Simon, William ;
Dresser, Sean ;
Serago, Christopher ;
Aguirre, Francisco ;
Ma, Lijun ;
Arjomandy, Bijan ;
Liu, Chihray ;
Sandin, Carlos ;
Holmes, Todd .
MEDICAL PHYSICS, 2009, 36 (09) :4197-4212
[9]  
Krishnan J, 2017, J MED PHYS, V42, P14, DOI 10.4103/jmp.JMP_112_16
[10]   Optimal beam arrangement for stereotactic body radiation therapy delivery in lung tumors [J].
Lim, Do Hoon ;
Yi, Byong Yong ;
Mirmiran, Ali ;
Dhople, Anil ;
Suntharalingam, Mohan ;
D'Souza, Warren D. .
ACTA ONCOLOGICA, 2010, 49 (02) :219-224